Skip to main content

Table 1 Patient information and clinical features of the CR-hvKP isolates

From: Isolation and characterization of a sequence type 25 carbapenem-resistant hypervirulent Klebsiella pneumoniae from the mid-south region of China

Strain Number

Patient Number

Age-range

Department

Collection Date

Source

Outcome

Resistance Determinants Genes

PFGE type

MLST

CS1

P2

21–30

ICU

2016/12/27

csf

Death

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS11

P1a

41–50

ICU

2016/11/28

sp

Survived

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS12

P1

41–50

ICU

2016/12/6

sp

Survived

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS15

P3a

51–60

IMD

2016/12/21

sp

Survived

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS17

P4

71–80

ICU

2016/12/3

sp

Giving up Treatmentb

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS45

P5

41–50

ICU

2016/11/15

sp

Giving up treatment

blaKPC-2, blaTEM-1, blaCTX-M-3

A

25

CS47

P6

71–80

ICU

2016/12/28

blood

Giving up treatment

blaKPC-2, blaTEM-1, blaCTX-M-3

A

25

CS48

P3

51–60

IMD

2016/12/31

sp

Survived

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS57

P3

51–60

IMD

2017/3/11

sp

Survived

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3

A

25

CS60

P14

61–70

CSD

2017/6/16

puncture fluid

Giving up treatment

bla SHV-1

H

25

CS61

P15

31–40

ICU

2017/6/4

drainage liquid

Death

bla SHV-1

H

25

CS62

P8

51–60

ICU

2017/6/16

sp

Survived

bla SHV-1

C

25

CS70

P1

41–50

RD

2017/6/22

sp

Survived

blaTEM-1, blaCTX-M-3

A

25

CS80

P13

61–70

Burn Unit

2017/7/2

traumatic secretion

Death

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-65

G

11

CS90

P9

51–60

Outpatient

2017/3/27

drainage liquid

Survived

blaSHV-1, blaCTX-M-65

D

375

CS103

P11

41–50

ICU

2017/5/22

sp

Giving up treatment

blaKPC-2, blaSHV-1

F

11

CS118

P12

71–80

ICU

2017/3/18

sp

Giving up treatment

blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-65

F

11

CS127

P10

41–50

Outpatient

2017/5/11

blood

Survived

bla SHV-1

E

25

CS129

P1

41–50

ICU

2017/3/16

sp

Survived

blaKPC-2, blaSHV-1, blaCTX-M-3

A

25

CS59497

P7

51–60

ICU

2014/10/5

sp

Survived

blaNDM-1, blaSHV-1, blaTEM-1

B

25

  1. Department: indicates the department at the Xiangya Hospital, where the samples were collected; ICU Intensive care unitm, IMD Integrative Medicine Department, CSD Cerebrovascular Surgery Department, RD Rehabilitation Department, mCIM Modified Carbapenem Inactivation Method, PFGE Pulsed Field Gel Electrophoresis, MLST Multilocus sequence type
  2. “CSF” Cerebrospinal fluid, “Sp” Sputum
  3. aPatients P1 and P3 are immunocompromised patients. Repeated infections occurred in these two patients during 2016 and 2017
  4. bThe patient’s condition deteriorated so the patient stopped any further treatment
Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us